Ishita Drugs Q1 FY27 Results: Revenue Rs 3 Cr, PAT Rs 0.23 Cr and Key Highlights
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Ishita Drugs Q1 FY27 results declared August 8, 2026. Revenue Rs 3 Cr (-41.76% YoY). PAT Rs 0.23 Cr (-23.85% YoY). CMP Rs 74.37 (+1.3%).
Ishita Drugs Q1 FY27 results were announced on August 8, 2026, standalone. Revenue declined -41.76% YoY to Rs 3 Cr from Rs 5.00 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 0.27 Cr (-15.93% YoY). PAT came in at Rs 0.23 Cr (-23.85% YoY), offering a comprehensive view of how Ishita Drugs is navigating the current pharmaceuticals environment.
Click Here – Get Free Investment Predictions
Ishita Drugs Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Ishita Drugs Revenue | 3 | 5.00 | -41.76% |
| Operating Profit | 0.27 | 0.32 | -15.93% |
| Net Profit (PAT) | 0.23 | 0.30 | -23.85% |
| Reporting Basis | Standalone | ||
Ishita Drugs Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Ishita Drugs Q1 FY27 results reflect under-pressure fundamentals across key financial metrics. Revenue faced near-term headwinds with the top line reaching Rs 3 Cr for the April to June 2026 quarter.
Operating profit contracted -15.93% YoY to Rs 0.27 Cr. Management is focused on cost rationalisation to restore operating leverage.
PAT of Rs 0.23 Cr marks a -23.85% YoY movement in Ishita Drugs Q1 FY27 results. Investors monitoring Ishita Drugs Q1 FY27 results will note this as a key FY27 performance milestone.
Key Business Factors in Ishita Drugs Q1 FY27 Results
Revenue Normalisation After Prior Period Headwinds
Ishita Drugs Q1 FY27 results reflect near-term revenue moderation of -41.76% YoY, attributed to demand normalisation, channel inventory adjustments, and competitive market dynamics in the pharmaceuticals space.
Margin Pressure from Cost Headwinds
Operating profit in Ishita Drugs Q1 FY27 results stood at Rs 0.27 Cr ((-15.93% YoY)), reflecting input cost inflation, wage pressures, and competitive pricing dynamics in the pharmaceuticals business.
PAT Performance and Profitability Trend
Net profit (PAT) in Ishita Drugs Q1 FY27 results stood at Rs 0.23 Cr ((-23.85% YoY)). Near-term PAT moderation is being managed through cost optimisation and revenue diversification.
Dividend Details
No dividend was announced alongside Ishita Drugs Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.
FY27 Outlook for Ishita Drugs
Following Ishita Drugs Q1 FY27 results, management has reiterated a recovery-focused strategy targeting operational efficiencies, cost rationalisation, and revenue diversification. The pace of recovery in the pharmaceuticals segment will be a key monitorable for investors tracking Ishita Drugs Q1 FY27 results. Consult a SEBI-registered financial advisor before making decisions.
Ishita Drugs Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Ishita Drugs live price and get daily stock recommendations.
Ishita Drugs shares were trading higher at Rs 74.37 (+1.3%) on August 8, 2026, reflecting investor sentiment on the Ishita Drugs Q1 FY27 results and near-term sector outlook. The CMP of Rs 74.37 on the results date reflects broader market and sector sentiment in the pharmaceuticals space.
Key Risks for Ishita Drugs
Sector-Specific Risks
USFDA regulatory actions, pricing pressure, and API cost inflation are core risks.
Valuation and Earnings Risk
Sustained earnings pressure may delay re-rating; near-term earnings visibility remains limited.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.
Conclusion
Ishita Drugs Q1 FY27 results reflect under-pressure performance with revenue at Rs 3 Cr and PAT at Rs 0.23 Cr on a Standalone basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Ishita Drugs Q1 FY27 Results
When were Ishita Drugs Q1 FY27 results declared?
Ans. Ishita Drugs Q1 FY27 results were declared on August 8, 2026, covering the April to June 2026 quarter on a Standalone basis.
What was Ishita Drugs revenue in Q1 FY27?
Ans. Ishita Drugs Q1 FY27 results show revenue of Rs 3 Cr, -41.76% compared to Rs 5.00 Cr in Q1 FY26.
What was Ishita Drugs PAT in Q1 FY27?
Ans. Net profit in Ishita Drugs Q1 FY27 results was Rs 0.23 Cr, -23.85% year-on-year.
Did Ishita Drugs declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Ishita Drugs Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.
What is the FY27 outlook for Ishita Drugs?
Ans. Management has guided operational restructuring and return to profitability for FY27. Sector trends and order visibility will be key monitorables for investors.
How did Ishita Drugs stock react to Q1 FY27 results?
Ans. Ishita Drugs shares were trading higher at Rs 74.37 (+1.3%) on August 8, 2026 following the Ishita Drugs Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.
